Solid Biosciences (NASDAQ:SLDB) Price Target Cut to $14.00 by Analysts at Wedbush

Key Points

• Wedbush has lowered the price target for Solid Biosciences (NASDAQ:SLDB) from $17.00 to $14.00 while maintaining an "outperform" rating, indicating a potential upside of 125.26% from its current price.
• Solid Biosciences's stock recently increased by 2.9% to $6.22, with a 12-month low of $2.41 and a high of $10.37.
• Institutional investors hold approximately 81.46% of the company's stock, with several firms significantly increasing their positions during the second quarter.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) had its target price reduced by analysts at Wedbush from $17.00 to $14.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Wedbush's price objective would indicate a potential upside of 129.13% from the company's previous close. Wedbush also issued estimates for Solid Biosciences' Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.75) EPS, Q1 2026 earnings at ($0.41) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($1.56) EPS, FY2027 earnings at ($1.58) EPS, FY2028 earnings at ($1.26) EPS and FY2029 earnings at ($0.50) EPS.

Several other brokerages have also recently commented on SLDB. HC Wainwright reissued a "buy" rating and issued a $20.00 price target on shares of Solid Biosciences in a research note on Tuesday, June 17th. JMP Securities reissued a "market outperform" rating and issued a $15.00 price target on shares of Solid Biosciences in a research note on Friday, June 6th. Barclays lowered their price target on Solid Biosciences from $15.00 to $10.00 and set an "overweight" rating for the company in a research note on Friday, May 16th. Chardan Capital lowered their price target on Solid Biosciences from $16.00 to $15.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Finally, Citigroup began coverage on Solid Biosciences in a research note on Thursday, June 26th. They issued a "buy" rating and a $14.00 price target for the company. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $15.00.

Solid Biosciences Trading Down 1.0%

NASDAQ:SLDB traded down $0.06 on Wednesday, hitting $6.11. 885,619 shares of the company's stock traded hands, compared to its average volume of 1,505,004. Solid Biosciences has a 1 year low of $2.41 and a 1 year high of $10.37. The firm has a 50-day moving average price of $5.62 and a 200-day moving average price of $4.44. The company has a market cap of $475.79 million, a PE ratio of -2.18 and a beta of 2.44.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.09. On average, research analysts forecast that Solid Biosciences will post -2.84 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Bridgeway Capital Management LLC lifted its holdings in shares of Solid Biosciences by 18.0% during the second quarter. Bridgeway Capital Management LLC now owns 98,531 shares of the company's stock worth $480,000 after buying an additional 15,000 shares during the last quarter. Birchview Capital LP lifted its holdings in shares of Solid Biosciences by 38.8% during the second quarter. Birchview Capital LP now owns 178,768 shares of the company's stock worth $871,000 after buying an additional 50,000 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Solid Biosciences by 2,150.4% during the second quarter. Bank of America Corp DE now owns 824,600 shares of the company's stock worth $4,016,000 after buying an additional 787,957 shares during the last quarter. Nantahala Capital Management LLC lifted its holdings in shares of Solid Biosciences by 505.4% during the second quarter. Nantahala Capital Management LLC now owns 1,703,336 shares of the company's stock worth $8,295,000 after buying an additional 1,421,968 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Solid Biosciences by 168.1% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,143 shares of the company's stock worth $176,000 after buying an additional 22,663 shares during the last quarter. 81.46% of the stock is currently owned by institutional investors and hedge funds.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.